In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
CBER Releases Updated RMAT Designation Requests, Approvals and Withdrawals
February 12, 2025
New Analysis Finds No Link Between CAR T-Cell Therapy, Secondary Cancers
February 05, 2025
REGULATORY UPDATE: Blood Community Submits Comments on HCT/P Draft Guidances
February 05, 2025